A whirlwind's winning ways

Same author

Plain language summary: Headache and migraine experiences in people with primary immunodeficiency receiving GAMMAPLEX® 5% or 10% intravenous immunoglobulin therapy.

Immunotherapy·2026

Same author

Protective antibody concentrations in primary immunodeficiency following infusion with 5% or 10% intravenous immunoglobulin.

Allergy and asthma proceedings·2024

Same author

Corrigendum: Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency.

Frontiers in immunology·2024

Same author

A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold.

Therapeutic advances in respiratory disease·2024

Same author

Hereditary factor X deficiency in America survey: impact on quality of life and burden of disease in patients and caregivers.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2024

Same author

Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency.

Frontiers in immunology·2023

Related Experiment Videos

A whirlwind's winning ways

Related Concept Videos

Plain language summary: Headache and migraine experiences in people with primary immunodeficiency receiving GAMMAPLEX® 5% or 10% intravenous immunoglobulin therapy.

Protective antibody concentrations in primary immunodeficiency following infusion with 5% or 10% intravenous immunoglobulin.

Corrigendum: Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency.

A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold.

Hereditary factor X deficiency in America survey: impact on quality of life and burden of disease in patients and caregivers.

Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency.

Related Experiment Videos

A whirlwind's winning ways

Related Concept Videos

Plain language summary: Headache and migraine experiences in people with primary immunodeficiency receiving GAMMAPLEX® 5% or 10% intravenous immunoglobulin therapy.

Protective antibody concentrations in primary immunodeficiency following infusion with 5% or 10% intravenous immunoglobulin.

Corrigendum: Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency.

A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold.

Hereditary factor X deficiency in America survey: impact on quality of life and burden of disease in patients and caregivers.

Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency.

Related Experiment Videos

A whirlwind's winning ways

Related Concept Videos

Related Articles

Plain language summary: Headache and migraine experiences in people with primary immunodeficiency receiving GAMMAPLEX® 5% or 10% intravenous immunoglobulin therapy.

Protective antibody concentrations in primary immunodeficiency following infusion with 5% or 10% intravenous immunoglobulin.

Corrigendum: Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency.

A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold.

Hereditary factor X deficiency in America survey: impact on quality of life and burden of disease in patients and caregivers.

Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency.

Related Experiment Videos

A whirlwind's winning ways

Related Concept Videos

Related Articles

Plain language summary: Headache and migraine experiences in people with primary immunodeficiency receiving GAMMAPLEX® 5% or 10% intravenous immunoglobulin therapy.

Protective antibody concentrations in primary immunodeficiency following infusion with 5% or 10% intravenous immunoglobulin.

Corrigendum: Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency.

A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold.

Hereditary factor X deficiency in America survey: impact on quality of life and burden of disease in patients and caregivers.

Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency.